Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 10/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352233 | 1.00 | PTGES (0.50) | PTGESSMN1; SMN2MAPTRAB9ALRRK2 | |
| SCHEMBL16503259 | 0.94 | PTGES (0.48) | PTGESSMN1; SMN2MAPTRAB9ALRRK2 | |
| SCHEMBL16352234 | 0.94 | PTGES (0.48) | PTGESSMN1; SMN2MAPTRAB9ALRRK2 | |
| SCHEMBL16318435 | 0.92 | PTGES (0.49) | PTGESSMN1; SMN2RAB9AHTR4HDAC11 | |
| SCHEMBL16509616 | 0.91 | PTGES (0.61) | PTGESLRRK2CRHR1 | |
| SCHEMBL16503254 | 0.91 | PTGES (0.51) | PTGESRAB9ALRRK2CRHR1 | |
| SCHEMBL1973380 | 0.91 | PTGES (0.61) | PTGESLRRK2CRHR1 | |
| SCHEMBL16352218 | 0.91 | PTGES (0.51) | PTGESRAB9ALRRK2CRHR1 | |
| SCHEMBL16352231 | 0.91 | PTGES (0.52) | PTGESSMN1; SMN2MAPTRAB9ACRHR1 | |
| SCHEMBL16318477 | 0.91 | PTGES (0.48) | PTGESRAB9ALRRK2HTR4CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | PTGES 118/4885SMN1; SMN2 3446/4885MAPT 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.